No Data
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 3.87 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNZZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$Ligand
10-Q: Q3 2024 Earnings Report
8-K: Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
LIGAND PHARMACEUTICAL INC (LGNYZ.US) will release financial reports before the market opens on November 7th.
$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$ will release its financial report before the market opens on November 7. Investors are kindly requested to pay attention. Futubull reminder: 1. There is no strict requirement for the division of fiscal year for Hong Kong-listed and US-listed companies, completely determined by the company itself, therefore, each financial report period can serve as the company's annual report deadline, instead of following the calendar year as the fiscal year. 2. Generally, the company will hold a financial report conference on the aforementioned financial report release date or around that date, where the company management will discuss the latest quarterly financial data and operational situation.
10-Q: Q2 2024 Earnings Report
8-K: Ligand Reports Second Quarter 2024 Financial Results
No Data
No Data